Skip to main content

Table 2 Safety and efficacy results from clinical trials of blinatumomab

From: Recent updates for antibody therapy for acute lymphoblastic leukemia

Type R/R Ph R/R Ph+ MRD+
Ref [44] [43] [45] [46] [48] [49]
Regimen BLN BLN BLNvs SOC BLN BLN BLN
Capacity 36 189 405 45 21 116
 ≥ second salvage 21% 39% 45% 82%   36%
Response CR/CRh: 69% CR/CRh: 43% CR: 34% CR/CRh/ CRi: 44% CR: 31% CR/CRh: 36% MRD response: 80% MRD response: 78%
OS (median) 9.8 6.1 7.7 7.1 36.5
Grade3 + neurotoxity 16% 11% 9% 7% 19% 13%
Grade3 + CRS 6% 2% 5% 0% 0% 2%
  1. MRD minimal residual disease, CRS cytokine release syndrome, Ref. reference number, R/R relapsed/refractory, Ph Philadelphia chromosome, BLN blinatumomab, SOC standard of care, CR complete response, CRh complete response with partial hematologic recovery, CRi complete response with incomplete hematologic recovery, OS overall survival